Introduction
IDC is a group of malignant epithelial tumors that tend to invade adjacent tissues and metastasize to distant sites [7] . Nuclear atypia and pleomorphism of IDC are consistent with PLC [8] . The biological aggression of PLC is related to the genetic alterations of high-grade ductal carcinoma, such as overexpression of c-myc and HER2/ neu5. Monhollen and Middleton [9, 10] suggested that PLC carried a higher risk of metastasis and recurrence than IDC. They also demonstrated that PLC had been associated with older age and postmenopausal status. Jung et al. [11] and Jung et al. [12] elucidated that PLC patients tend to be older, to have larger tumor, and to exhibit more axillary LN involvement (higher T and N stages) compared to IDC patients.
Because the incidence of PLC is low, most of the available studies are small retrospective studies or case reports. For this reason, we aim to compare survival outcomes of PLCs with IDCs with large amount of cases and identify prognostic factors that lead to survival differences between the histologic subtypes of breast cancer using the 3 Including American Indian/Alaskan native, Asian/Pacific Islander, and others-unspecified. 4 Including divorced, separated, single (never married), and widowed.
Survival Outcomes in PLC L.-P. Yang et al. Figure 1 . The disease-specific survival and disease-overall survival of the two groups. Kaplan-Meier test for disease-specific survival (χ 2 = 7.937, P = 0.0078, Fig. 1A ) and disease-overall survival (χ 2 = 6.619, P = 0.0036, Fig. 1B ) to compare PLC patients and IDC patients. Multivariate analysis included year of diagnosis, age at diagnosis, race, marital status, laterality, grade, histology, LN status, ER/PR status, surgery type and radiation. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node; PR, progesterone receptor. The bold number of p-value is statistically significant 1 Including American Indian, Alaska Native, Asian, Pacific Islander and others-unspecified. 2 Including divorced, separated, single (never married), and widowed.
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Surveillance, Epidemiology, and End Result (SEER) database. We find 131 available PLC cases, so the statistical result we get will be more accurate.
Materials and Methods

Patient selection and data acquisition
The SEER data we use was released in April 2016, which includes data from 18 population-based registries. The data covers the period from 1973 to 2013. The data of tumor grade, location, and histology are recorded according to the International Classification of Diseases for Oncology Version 3 (ICD-O-3). The patient's inclusion criteria were as follows: patients age older than 15, breast cancer (ICD-O-3 site code C50), unilateral breast cancer as the first and only cancer diagnosis, diagnosis not obtained from autopsy or a death certificate, there was only one major site, pathologically confirmed invasive ductal carcinoma no other specified (ICD-O-3 8500/3) 
Statistical analysis
The clinical and pathological features are compared using Pearson's chi-square test or Fisher's exact test for classification of nominal data and Cochran-Mantel-Haenszel (CMH) chi-square test for classification of nominal data. The Kaplan-Meier method is performed to generate 5-year disease-specific survival curves, and log-rank test is performed to compare the difference between curves. In order to eliminate the influencing factors other than the disease type between the two group and get more accurate results, we match every PLCs to IDCs based on the following factors: race, age, year of diagnosis, laterality, PR status, tumor grade, marital status, LN status, tumor stage, ER status, surgery type and radiation. We use propensity score matching method in SPSS and to test match quality to determine the matching balance. All analyzes are performed with the SPSS statistical software, 24.0 version (Armonk, NY, IBM Crop). A two-sided P < 0.05 is considered to indicate statistical significance. 
Results
Clinicopathological features of PLC and IDC
According to the criteria we set, we selected 460,240 patients with breast cancer, including 131 PLC patients and 460,109 IDC patients. The tumor demographics and treatment characteristics of histological subtypes are summarized in Table 1 . Tumor characteristics with significant statistical differences included histological grade, AJCC stage, and LN status. PLC patients presented with higher grade (grade III: 43.6% vs. 37.3%; P < 0.01) and higher AJCC stage than IDC patients (stage III: 19.1% vs. 11.8% and stage IV: 3.80% vs. 3.40%, respectively; P < 0.01). The PLC patients have more LN-positive than IDC patients (LN positive: 42.7% vs. 29.9% P < 0.01) and lower median survival months (PLC 84 ± 51.03 vs. IDC 105.2 ± 64.39 P < 0.01) than IDC patients. In the Black race and unmarried population, the proportion of PLC patients was higher than in IDC patients (16.0% vs. 9.1% P = 0.018; 14.5% vs. 12.3% P = 0.023, respectively). The two groups were treated differently. Mastectomy rate was higher in PLCs than in IDCs (54.2% vs. 30.4%; P < 0.01). PLC patients prefer to be less likely to receive radiation therapy than IDC (57.3% vs. 50.9% P = 0.048). We did not find significant difference in laterality, ER, and PR.
Comparison of survival outcome between PLCs and IDCs
We use Kaplan-Meier plots to evaluate DSS and OS of these two histologic subtypes (Fig. 1A and B) . IDCs have better DSS and OS than the overall PLC population (χ 2 = 7.937, P = 0.0078; χ 2 = 6.619, P = 0.0036). Fiveyear DSS rate of IDC and PLC were 89.0% and 84.7%, respectively. Five-year OS rate of IDC and PLC were 80.3% and 73.5%, respectively. We used a Cox proportional hazards model to study the effects of baseline characteristics on DSS with univariate and multivariate analysis ( Table 2 ). In the univariate analysis, the prognostic indicators were significantly associated with DSS including patients diagnosed after 2000, patients diagnosed after the age of 50, Black race, higher grade, higher AJCC stage, LN positive, ER/PR negative, no surgery, and radiation. These variables were included in multivariate analysis. The results of multivariate analysis confirmed the prognostic factors of univariate analysis. However, after adjusting for other prognostic factors, the histological type was no longer an independent prognostic factor in multivariate analysis (P = 0.120).
The survival analysis of the matched group
In order to ensure that the difference in survival results is not based on the histological subgroup of demographic and clinical characteristics of the baseline differences, we use the propensity score matching method to perform a 1:1 (IDC: PLC) matched case-control analysis. We obtained 234 patients, of which 117 cases were of PLC, and the remaining117 cases of IDC (Table 3) . We used the Cox proportional hazards model for univariate and multivariate analysis to study the effect of baseline characteristics on DSS (Table 4) . For matched groups, we find that there is no statistically significant difference in DSS and OS between PLCs and IDCs ( Fig. 2A χ 2 
The baseline and survival outcomes of ER-positive subgroups
The proportion of patients with ER positive in PLC and IDC is high and we observed some results in these patients. (Table 5 ). ER-positive PLC patients had higher tumor grade, higher AJCC stage, and shorter median survival months than ER-positive IDC patients. However, there was no statistically significant difference in LN status between ER-positive PLC patients and ER-positive IDC patients. Compared with the two groups of ER-positive patients, there was no statistically significant difference in DSS and OS curves (Fig. 3A P = 0.1521; Fig. 3B , P = 0.3675).
Discussion
With the increasing incidence of breast cancer, the incidence of PLC may also increase. Therefore, it is necessary to obtain more knowledge about the clinical and biological characteristics of the PLC. The factors that limit the current research on PLC are small sample size and short follow-up time. Therefore, previous studies lack accurate research conclusions about the clinical behavior, prognosis, and treatment strategy of PLC.
This study is the largest analysis of the sample size of PLC. In this study, we retrospectively observed the clinical and pathological characteristics of PLC based on a large number of people. What we found indicated that PLCs Limited information about PLC has been reported in previous studies. Jung and Jung [11, 12] observed that PLCs tend to be older, have larger tumors, and to exhibit more axillary LN involvement (higher T and N stages) than IDCs. In addition, PLCs often display evidence of lymph vascular invasion and a higher proliferative index [13] . Most evidence point to PLCs having a lobular origin that develops into a more aggressive phenotype [14, 15] . Studies performed earlier showed ER/PR positivity of 9% to 20% in PLC [13, 16] . Later publications, however, demonstrate ER/PR positivity of 57% to 96% in PLC [17, 18] . Monhollen et al. elucidated that PLC carry with it a higher risk of metastasis and recurrence then IDC.
However, our research has several shortcomings inevitably. First, the current SEER database does not contain the records of adjuvant chemotherapy Ki-67 expression and endocrine therapy, so we cannot get some important prognostic factors. Second, because Her-2 was documented in the seer database only after 2010, our data which were collected from 1990 to 2009, did not include that factor. Third, we used propensity score matching method to accomplish our match. In the procedure, 117 IDCs matched with random selection of 117 patients from the patient population may be the reason for the bias sampling, reducing the actual effect of this study.
Compared with IDC, we found that PLC has unique clinicopathological characteristics associated with poor prognosis. However, after we adjust the demographic and clinical pathology factors, this disadvantage is weakened. Improving the clinical and biological understanding of PLC may lead to more personalized and customized treatment for breast cancer patients.
